• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Weekly Paclitaxel does not prolong progression-free survival in ovarian cancer

byNeil D'SouzaandShaidah Deghan, MSc. MD
February 25, 2016
in Chronic Disease, Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. A weekly dosing regimen of Paclitaxel versus the standard dosing of Paclitaxel every 3 weeks, both administered with equal Carboplatin and Bevacizumab doses, did not show a progression-free survival benefit amongst patients with ovarian cancer.

2. Weekly Paclitaxel and Carboplatin given without Bevacizumab led to an increase in progression-free survival when compared to the 3-weekly regimen, but this outcome was still shorter than the weekly and every-3-weekly Paclitaxel, Carboplatin and Bevacizumab regimen.

Evidence Rating Level: 1 (Excellent)      

Study Rundown:  Ovarian cancer is considered to be the most lethal of the gynaecologic malignancies, given its vague and late presenting signs and symptoms. Monoclonal antibody Bevacizumab has shown activity against vascular endothelial growth factor in ovarian cancers, prolonging progression-free survival, but not overall survival. Conventional chemotherapy regimens involve Paclitaxel administered every 3 weeks, along with carboplatin. Further, dose-dense weekly Paclitaxel has demonstrated prolonged progression-free and overall survival in ovarian cancer, when compared to treatment given every 3 weeks. However, no study has compared weekly vs every-3-wk Paclitaxel and Carboplatin, with or without Bevacizumab. In carrying out such a comparison, this RCT showed no increase in progression-free survival weekly versus every-3-wk Paclitaxel (in combination with Carboplatin).  However, treatment with and without Bevacizumab in context of the above comparison did show a significant treatment difference, with Bevacizumab increasing progression-free survival. Statistically significant sequelae associated with the weekly dose-dense Paclitaxel included increased rates of grade 3/4 anemia and grade 2-4 sensory neuropathy. While a key strength of this study was being a RCT with a large number of patients across different centres, the main limitation of this study lies in the non-randomization of Bevacizumab use, and its affect on weekly vs every-3-wk Paclitaxel administration. Nevertheless, the study has important clinical implications in that it presents different treatment options for ovarian cancer patients, especially for those having increased sensitivity to paclitaxel or resistance to platinum based chemotherapies.

Click to read the study in NEJM

Relevant Reading: Incorporation of bevacizumab in the primary treatment of ovarian cancer

RELATED REPORTS

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

#VisualAbstract: No difference in survival between fluorouracil, cisplatin, or carboplatin-based paclitaxel therapy for locally advanced esophageal squamous cell carcinoma

In-Depth [randomized controlled trial]:  This phase III randomized control trial compared two ovarian cancer treatment regimens: weekly Paclitaxel (80 mg per square meter BSA) plus Carboplatin for 6 cycles, vs every-3-wk Paclitaxel (175 mg per square meter BSA) plus Carboplatin for 6 cycles. Prior to this randomization, patients were prospectively stratified according to whether they wished to receive Bevacizumab. The primary outcome measure was progression-free survival.

A total of 692 patients with newly diagnosed, previously untreated ovarian cancer between Sept/2010 and Feb/2012 across 209 clinics in the United States, Canada, and South Korea were enrolled in the study. A total of 580 patients (84%) opted to receive Bevacizumab.  At a median follow-up of 28 months, 67% of patients were alive. The overall intention-to-treat analysis demonstrated weekly Paclitaxel did not prolong progression-free survival compared to Paclitaxel administration every 3 weeks (14.7 months vs. 14.0 months, respectively; HR for disease progression or death, 0.89; 95% [CI], 0.74 – 1.06; p=0.18).  For patients who opted to not receive Bevacizumab, weekly Paclitaxel was associated with a median progression-free survival increase of 3.9 months compared to every-3-wk Paclitaxel (14.2 months vs. 10.3 months; HR=0.62; 95% [CI], 0.40 – 0.95; p=0.03).  For patients who choose to receive, Bevacizumab, there was no difference in progression-free survival between weekly and every-3-wk Paclitaxel (14.9 months vs. 14.7 months; HR=0.99; 95% [CI], 0.83-1.2; P=0.60). In terms of side effects, patients receiving Paclitaxel weekly had a higher rate of grade 3 or 4 anemia compared to those receiving Paclitaxel every 3 weeks (36%vs.16%), and higher rates of grade 2-4 sensory neuropathy (26% vs.18%).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ovarian cancerpaclitaxel
Previous Post

Drug reformulation may improve treatment of Niemann-Pick type C disease [PreClinical]

Next Post

Pre-operative aspirin not linked with improved outcomes during CABG

RelatedReports

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
StudyGraphics

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

April 27, 2022
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
#VisualAbstract: Delayed receipt of adjuvant hormone therapy is associated with worse survival in HR⁺, ERBB2- breast cancer
StudyGraphics

#VisualAbstract: No difference in survival between fluorouracil, cisplatin, or carboplatin-based paclitaxel therapy for locally advanced esophageal squamous cell carcinoma

March 9, 2022
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Chronic Disease

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

February 15, 2022
Next Post
Cognitive outcomes in older adults undergoing cardiovascular procedures unclear

Pre-operative aspirin not linked with improved outcomes during CABG

Smoking during pregnancy associated with aerobic fitness of children

Text-message reminders associated with improved smoking cessation amongst young-adults

Disparities in type 1 diabetes not explained by socioeconomic status alone

Positive outcomes for supported, socially transitioned transgender children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer
  • Several factors influence health programs conducted in the African American Church
  • Imiquimod noninferior to surgery in management of vulvar high-grade squamous intraepithelial lesions
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.